21 CFR 1.633
§ 1.633 How will FDA monitor recognized accreditation bodies?
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 1.633, § 1.633 How will FDA monitor recognized accreditation bodies?, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/82835
- Permanent ID
ys:prov:82835@1- SHA-256
9622a4cca72c49a065a5a9f77b164b7204d80d3c2fdbccb32181172d77242e73
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) FDA will evaluate the performance of each recognized accreditation body to determine its compliance with the applicable requirements of this subpart. Such assessment must occur by at least 4 years after the date of recognition for a 5-year recognition period, or by no later than the mid-term point for a recognition period of less than 5 years. FDA may conduct additional assessments of a recognized accreditation body at any time.
(b) An FDA assessment of a recognized accreditation body may include onsite assessments of a representative sample of third-party certification bodies the recognized accreditation body accredited and onsite audits of a representative sample of eligible entities certified by such third-party certification bodies under this subpart. These may be conducted at any time and, as FDA determines necessary or appropriate, may occur without the recognized accreditation body or, in the case of an audit of an eligible entity, the accredited third-party certification body present.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.